RESUMEN
INTRODUCTION: Cardiac involvement may occur in many forms of muscular dystrophy (MD). While cardiac disease may progress to warrant heart transplantation (HTx), there may be contraindications related to extra-cardiac disease including pulmonary and skeletal muscle involvement that limit overall survival and impairs post-transplant rehabilitation efforts. This study describes the MD HTx experience at a single high-volume center. METHODS: We examined the clinical characteristics and outcomes of patients with MD with heart failure (HF) (n = 28), patients with MD status post HTx (n = 20) and non-MD HTx control group (n = 40) matched 2:1 for age at transplant, sex, listing status, and antibody sensitization. RESULTS: Patients with MD who underwent HTx had increased ventilator days (2 vs. 1 days, p = .013), increased hospital length of stay (20 vs. 12 days, p = .022), and increased discharge to inpatient rehab (60% vs. 8%, p < .001). By 1 year post HTx, patients with MD more often required assistive devices for walking (55% vs. 10%, p = .01). Nonetheless, post-HTx survival was similar at 1 year (100% vs. 97.5%, p = .48) and 5 years (95.0% vs. 87.5%, p = .36). Of the HTx recipients with MD, 95% were followed by a neurologist, 60% by a neuromuscular specialist as part of the Muscular Dystrophy Association Clinic at our center. CONCLUSION: Transplantation is a feasible option for patients with MD and advanced HF. MD patients who undergo transplantation may benefit from multidisciplinary specialized care to optimize MD-related morbidity.
Asunto(s)
Cardiopatías , Insuficiencia Cardíaca , Trasplante de Corazón , Distrofias Musculares , Cardiopatías/etiología , Insuficiencia Cardíaca/cirugía , Trasplante de Corazón/efectos adversos , Humanos , Distrofias Musculares/etiología , Distrofias Musculares/cirugía , Factores de Riesgo , Factores de Tiempo , Resultado del TratamientoRESUMEN
Emerin is the inner nuclear membrane protein involved in maintaining the mechanical integrity of the nuclear membrane. Mutations in EMD encoding emerin cause Emery-Dreifuss muscular dystrophy (EDMD). Evidence is accumulating that emerin regulation of specific gene expression is associated with this disease, but the exact function of emerin has not been fully elucidated. Here, we show that emerin downregulates Signal transducer and activators of transcription 3 (STAT3) signaling, activated exclusively by Janus kinase (JAK). Deletion mutation experiments show that the lamin-binding domain of emerin is essential for the inhibition of STAT3 signaling. Emerin interacts directly and co-localizes with STAT3 in the nuclear membrane. Emerin knockdown induces STAT3 target genes Bcl2 and Survivin to increase cell survival signals and suppress hydrogen peroxide-induced cell death in HeLa cells. Specifically, downregulation of BAF or lamin A/C increases STAT3 signaling, suggesting that correct-localized emerin, by assembling with BAF and lamin A/C, acts as an intrinsic inhibitor against STAT3 signaling. In C2C12 cells, emerin knockdown induces STAT3 target gene, Pax7, and activated abnormal myoblast proliferation associated with muscle wasting in skeletal muscle homeostasis. Our results indicate that emerin downregulates STAT3 signaling by inducing retention of STAT3 and delaying STAT3 signaling in the nuclear membrane. This mechanism provides clues to the etiology of emerin-related muscular dystrophy and may be a new therapeutic target for treatment.
Asunto(s)
Proteínas de la Membrana/metabolismo , Membrana Nuclear/metabolismo , Proteínas Nucleares/metabolismo , Factor de Transcripción STAT3/metabolismo , Transducción de Señal , Células A549 , Núcleo Celular/metabolismo , Supervivencia Celular , Regulación de la Expresión Génica , Humanos , Quinasas Janus/metabolismo , Músculo Esquelético/metabolismo , Distrofias Musculares/etiología , Distrofias Musculares/metabolismo , Distrofias Musculares/patología , Mutación , Unión Proteica , Factor de Transcripción STAT3/genética , Factores de Transcripción/metabolismoRESUMEN
Mutations in the lamin A/C gene (LMNA), which encodes A-type lamins, cause several diseases called laminopathies, the most common of which is dilated cardiomyopathy with muscular dystrophy. The role of Ca2+ regulation in these diseases remain poorly understood. We now show biochemical remodeling of the ryanodine receptor (RyR)/intracellular Ca2+ release channel in heart samples from human subjects with LMNA mutations, including protein kinase A-catalyzed phosphorylation, oxidation and depletion of the stabilizing subunit calstabin. In the LmnaH222P/H222P murine model of Emery-Dreifuss muscular dystrophy caused by LMNA mutation, we demonstrate an age-dependent biochemical remodeling of RyR2 in the heart and RyR1 in skeletal muscle. This RyR remodeling is associated with heart and skeletal muscle dysfunction. Defective heart and muscle function are ameliorated by treatment with a novel Rycal small molecule drug (S107) that fixes 'leaky' RyRs. SMAD3 phosphorylation is increased in hearts and diaphragms of LmnaH222P/H222P mice, which enhances NADPH oxidase binding to RyR channels, contributing to their oxidation. There is also increased generalized protein oxidation, increased calcium/calmodulin-dependent protein kinase II-catalyzed phosphorylation of RyRs and increased protein kinase A activity in these tissues. Our data show that RyR remodeling plays a role in cardiomyopathy and skeletal muscle dysfunction caused by LMNA mutation and identify these Ca2+ channels as a potential therapeutic target.
Asunto(s)
Cardiomiopatías/patología , Modelos Animales de Enfermedad , Corazón/fisiopatología , Lamina Tipo A/genética , Distrofias Musculares/patología , Mutación , Canal Liberador de Calcio Receptor de Rianodina/metabolismo , Animales , Señalización del Calcio , Cardiomiopatías/etiología , Cardiomiopatías/metabolismo , Femenino , Homeostasis , Humanos , Masculino , Ratones , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Distrofias Musculares/etiología , Distrofias Musculares/metabolismo , Canal Liberador de Calcio Receptor de Rianodina/genéticaRESUMEN
The aim of the study was to identify possible predictors of neurological worsening and need of non-invasive ventilation (NIV) in individuals affected by myotonic dystrophy type 1 (DM1), the most common form of adult-onset muscular dystrophy. METHODS: A retrospective observational cohort study was undertaken. Thirty-three patients with genetic diagnosis of DM1 were followed at our Neuromuscular unit in Modena. Abnormal trinucleotide repeat (CTG) expansion of dystrophy protein kinase gene (MDPK) on chromosome 19q 13.3 was the prerequisite for inclusion. The number of CTG repeats was determined. All the participants were older than 14 at the time of enrolment, therefore they could be included into the juvenile or adult form of the disease. Participants were neurologically evaluated every 6-8 months up to 18 years. Neurological impairment was assessed by Muscular Impairment Rating (MIRS), Medical Research Council (MRC), and modified Rankin (mRS) scales. The independent variables considered for prognosis were age at first evaluation, duration of the disease, CTG repeat number, gender, and presence of cardiac and vascular morbidities.Male patients were 51.5% and female patients 48.5%. Sixteen patients were younger than the mean age of 30.1 years, while the remaining 17 were up to 65. Twelve subjects (36.4%) underwent NIV before the end of follow-up. Muscle force and disability scores showed statistically significant deterioration (p < 0.001) during follow-up. The worsening was significantly higher among patients carrying higher number of CTG repeats and of younger age. The presence of cardio-vascular involvement has significant impact on neurological and respiratory progression.Neurological worsening is predicted by CTG expansion size, young age and presence of cardio-vascular morbidities.
Asunto(s)
Distrofias Musculares , Distrofia Miotónica , Enfermedades del Sistema Nervioso , Monitoreo Neuromuscular , Expansión de Repetición de Trinucleótido/genética , Adulto , Edad de Inicio , Enfermedades Cardiovasculares/epidemiología , Técnicas de Diagnóstico Neurológico , Evaluación de la Discapacidad , Progresión de la Enfermedad , Femenino , Humanos , Italia/epidemiología , Masculino , Distrofias Musculares/diagnóstico , Distrofias Musculares/etiología , Distrofia Miotónica/epidemiología , Distrofia Miotónica/genética , Distrofia Miotónica/fisiopatología , Proteína Quinasa de Distrofia Miotónica/genética , Enfermedades del Sistema Nervioso/etiología , Enfermedades del Sistema Nervioso/fisiopatología , Enfermedades del Sistema Nervioso/terapia , Monitoreo Neuromuscular/métodos , Monitoreo Neuromuscular/estadística & datos numéricos , Ventilación no Invasiva/estadística & datos numéricos , Pronóstico , Estudios RetrospectivosRESUMEN
The nuclear factor erythroid 2-related factor 2 (Nrf2) is considered as a master cytoprotective factor regulating the expression of genes encoding anti-oxidant, anti-inflammatory, and detoxifying proteins. The role of Nrf2 in the pathophysiology of skeletal muscles has been evaluated in different experimental models, however, due to inconsistent data, we aimed to investigate how Nrf2 transcriptional deficiency (Nrf2tKO) affects muscle functions both in an acute and chronic injury. The acute muscle damage was induced in mice of two genotypes-WT and Nrf2tKO mice by cardiotoxin (CTX) injection. To investigate the role of Nrf2 in chronic muscle pathology, mdx mice that share genetic, biochemical, and histopathological features with Duchenne muscular dystrophy (DMD) were crossed with mice lacking transcriptionally active Nrf2 and double knockouts (mdx/Nrf2tKO) were generated. To worsen the dystrophic phenotype, the analysis of disease pathology was also performed in aggravated conditions, by applying a long-term treadmill test. We have observed slightly increased muscle damage in Nrf2tKO mice after CTX injection. Nevertheless, transcriptional ablation of Nrf2 in mdx mice did not significantly aggravate the most deleterious, pathological hallmarks of DMD related to degeneration, inflammation, fibrotic scar formation, angiogenesis, and the number and proliferation of satellite cells in non-exercised conditions. On the other hand, upon chronic exercises, the degeneration and inflammatory infiltration of the gastrocnemius muscle, but not the diaphragm, turned to be increased in Nrf2tKOmdx in comparison to mdx mice. In conclusion, the lack of transcriptionally active Nrf2 influences moderately muscle pathology in acute CTX-induced muscle injury and chronic DMD mouse model, without affecting muscle functionality. Hence, in general, we demonstrated that the deficiency of Nrf2 transcriptional activity has no profound impact on muscle pathology in various models of muscle injury.
Asunto(s)
Distrofias Musculares/metabolismo , Factor 2 Relacionado con NF-E2/metabolismo , Animales , Cardiotoxinas/toxicidad , Distrofina/genética , Femenino , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos mdx , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Músculo Esquelético/fisiopatología , Distrofias Musculares/etiología , Distrofias Musculares/genética , Factor 2 Relacionado con NF-E2/genética , CarreraRESUMEN
The X-linked filaminopathies represent a diverse group of clinical conditions, all caused by variants in the gene FLNA. FLNA encodes the widely expressed actin binding protein, filamin A that has multiple roles during embryonic development including cell migration, mechanical sensing, and cell signaling. In this review, we discuss the 10 distinct X-linked filaminopathy conditions that between them affect almost all organ systems, including the brain, skeleton, heart, and skin, highlighting the critical role of this protein in human development. We review each of the phenotypes and discuss their pathogenesis, where known. Assigning pathogenicity to variants in FLNA can prove difficult, especially for missense variants and small indels, in-part because of the X-linked nature of the phenotypes, the overlap of phenotypic features between conditions, and poor understanding of the function of certain protein domains. We outline here approaches to characterize phenotypes, highlight hotspot regions within FLNA commonly mutated in these conditions, and approaches to resolving some variants of uncertain significance.
Asunto(s)
Filaminas/genética , Genes Ligados a X , Estudios de Asociación Genética , Predisposición Genética a la Enfermedad , Distrofias Musculares/diagnóstico , Distrofias Musculares/etiología , Mutación , Fenotipo , Alelos , Diagnóstico Diferencial , Facies , Filaminas/metabolismo , Mutación con Ganancia de Función , Regulación de la Expresión Génica , Pruebas Genéticas , Variación Genética , Humanos , Masculino , Distrofias Musculares/metabolismo , Especificidad de Órganos/genética , Radiografía , Transducción de SeñalRESUMEN
Multiple acyl-CoA dehydrogenase deficiency is a rare autosomal recessive inborn error of metabolism. The late-onset multiple acyl-CoA dehydrogenase deficiency is frequently caused by mutations in ETFDH gene. Because of its clinical heterogeneity, diagnosis and treatment of late-onset multiple acyl-CoA dehydrogenase deficiency are often delayed. The authors described a previously healthy 40-yr-old Thai woman presenting with subacute severe weakness of bulbar-limb muscles and elevated serum creatine kinase. The authors emphasized the importance of needle EMG and prompt muscle histopathological evaluation, which rapidly led to the diagnosis and riboflavin therapy, resulting in a dramatic and rapid improvement before genetic study disclosed mutation in ETFDH gene.
Asunto(s)
Electromiografía/métodos , Errores Innatos del Metabolismo Lipídico/etiología , Errores Innatos del Metabolismo Lipídico/fisiopatología , Deficiencia Múltiple de Acil Coenzima A Deshidrogenasa/complicaciones , Deficiencia Múltiple de Acil Coenzima A Deshidrogenasa/fisiopatología , Distrofias Musculares/etiología , Distrofias Musculares/fisiopatología , Adulto , Femenino , Humanos , Errores Innatos del Metabolismo Lipídico/tratamiento farmacológico , Errores Innatos del Metabolismo Lipídico/genética , Deficiencia Múltiple de Acil Coenzima A Deshidrogenasa/tratamiento farmacológico , Deficiencia Múltiple de Acil Coenzima A Deshidrogenasa/genética , Distrofias Musculares/tratamiento farmacológico , Distrofias Musculares/genética , Riboflavina/uso terapéuticoRESUMEN
Dystroglycan, an extracellular matrix receptor, has essential functions in various tissues. Loss of α-dystroglycan-laminin interaction due to defective glycosylation of α-dystroglycan underlies a group of congenital muscular dystrophies often associated with brain malformations, referred to as dystroglycanopathies. The lack of isogenic human dystroglycanopathy cell models has limited our ability to test potential drugs in a human- and neural-specific context. Here, we generated induced pluripotent stem cells (iPSCs) from a severe dystroglycanopathy patient with homozygous FKRP (fukutin-related protein gene) mutation. We showed that CRISPR/Cas9-mediated gene correction of FKRP restored glycosylation of α-dystroglycan in iPSC-derived cortical neurons, whereas targeted gene mutation of FKRP in wild-type cells disrupted this glycosylation. In parallel, we screened 31,954 small molecule compounds using a mouse myoblast line for increased glycosylation of α-dystroglycan. Using human FKRP-iPSC-derived neural cells for hit validation, we demonstrated that compound 4-(4-bromophenyl)-6-ethylsulfanyl-2-oxo-3,4-dihydro-1H-pyridine-5-carbonitrile (4BPPNit) significantly augmented glycosylation of α-dystroglycan, in part through upregulation of LARGE1 glycosyltransferase gene expression. Together, isogenic human iPSC-derived cells represent a valuable platform for facilitating dystroglycanopathy drug discovery and therapeutic development.
Asunto(s)
Evaluación Preclínica de Medicamentos , Distroglicanos/metabolismo , Células Madre Pluripotentes Inducidas/metabolismo , Secuencia de Bases , Sistemas CRISPR-Cas , Células Cultivadas , Evaluación Preclínica de Medicamentos/métodos , Distroglicanos/genética , Edición Génica , Marcación de Gen , Sitios Genéticos , Glicosilación/efectos de los fármacos , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Imagen Molecular , Distrofias Musculares/tratamiento farmacológico , Distrofias Musculares/etiología , Distrofias Musculares/metabolismo , Mutación , N-Acetilglucosaminiltransferasas/genética , N-Acetilglucosaminiltransferasas/metabolismo , Células-Madre Neurales/metabolismo , Neuronas/metabolismo , Pentosiltransferasa/genética , Pentosiltransferasa/metabolismoRESUMEN
Pluripotent stem cells (PSCs) represent an attractive cell source for treating muscular dystrophies (MDs) since they easily allow for the generation of large numbers of highly regenerative myogenic progenitors. Using reprogramming technology, patient-specific PSCs have been derived for several types of MDs, and genome editing has allowed correction of mutations, opening the opportunity for their therapeutic application in an autologous transplantation setting. However, there has been limited progress on preclinical studies that validate the therapeutic potential of these gene corrected PSC-derived myogenic progenitors. In this review, we highlight the major research advances, challenges, and future prospects towards the development of PSC-based therapeutics for MDs.
Asunto(s)
Distrofias Musculares/terapia , Células Madre Pluripotentes/citología , Células Madre Pluripotentes/metabolismo , Trasplante de Células Madre , Animales , Biomarcadores , Diferenciación Celular , Tratamiento Basado en Trasplante de Células y Tejidos/métodos , Modelos Animales de Enfermedad , Edición Génica , Terapia Genética , Humanos , Células Madre Pluripotentes Inducidas/citología , Células Madre Pluripotentes Inducidas/metabolismo , Distrofias Musculares/etiología , Mioblastos Cardíacos/citología , Mioblastos Cardíacos/metabolismo , Regeneración , Trasplante de Células Madre/métodos , TransgenesRESUMEN
Muscular dystrophy and dilated cardiomyopathy are intractable diseases and their treatment options are very limited. Transient receptor potential cation channel subfamily V, member 2 (TRPV2), is a stretch-sensitive Ca2+-permeable channel that causes sustained intracellular Ca2+ increase in muscular cells, which is a pathophysiological feature of degenerative muscular disease. Recent reports have clarified that TRPV2 is concentrated and activated in the sarcolemma of cardiomyocytes/myocytes during cardiomyopathy/heart failure and muscular dystrophy. Furthermore, these reports showed that inactivation of TRPV2 ameliorates muscle dysgenesis to improve cardiac function and survival prognosis. Although TRPV2 is a potential therapeutic target for cardiomyopathy, there were no TRPV2 inhibitors available until recently. In this review, we introduce our recent findings and discuss the current progress in the development of TRPV2 inhibitors and their therapeutic applications for cardiomyopathy associated with muscular dystrophy.
Asunto(s)
Cardiomiopatía Dilatada/tratamiento farmacológico , Cardiomiopatía Dilatada/etiología , Terapia Molecular Dirigida , Distrofias Musculares/complicaciones , Distrofias Musculares/metabolismo , Canales Catiónicos TRPV/antagonistas & inhibidores , Animales , Ensayos Clínicos como Asunto , Descubrimiento de Drogas , Expresión Génica , Humanos , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Distrofias Musculares/etiología , Dominios y Motivos de Interacción de Proteínas , Canales Catiónicos TRPV/química , Canales Catiónicos TRPV/genética , Canales Catiónicos TRPV/metabolismoRESUMEN
Muscular dystrophy describes generalized progressive muscular weakness due to the wasting of muscle fibers. The progression of the disease is affected by known immunological and mechanical factors, and possibly other unknown mechanisms. This article introduces a new mathematical model, the FRiND model, to further elucidate these known immunological actions. We will perform stability and sensitivity analyses on this model. The models time course results will be verified by biological studies in the literature. This model could be the foundation for further understanding of immunological muscle repair.
Asunto(s)
Macrófagos/inmunología , Modelos Inmunológicos , Distrofias Musculares/inmunología , Animales , Simulación por Computador , Humanos , Inmunidad Innata , Inflamación/etiología , Inflamación/inmunología , Inflamación/patología , Macrófagos/patología , Conceptos Matemáticos , Ratones , Ratones Endogámicos mdx , Músculo Esquelético/inmunología , Músculo Esquelético/patología , Distrofias Musculares/etiología , Distrofias Musculares/patología , Regeneración/inmunología , Biología de SistemasRESUMEN
Fundamento: el síndrome de Hoffmann es definido como la combinación de hipotiroidismo con miopatía, rigidez, calambres e hipertrofia muscular. Dicha forma de miopatía tiroidea es rara y por lo general acompaña a los pacientes con hipotiroidismo severo y de larga evolución. Objetivo: describir un caso con características clínicas, hormonales y musculares de un síndrome de Hoffmann, como manifestación excepcional del hipotiroidismo. Caso clínico: paciente femenina, de 16 años de edad comienza a sentir molestias musculares dadas por dolores y fatiga, las cuales se incrementaron de manera progresiva, las mialgias se tornaron intensas al punto que no le permitían realizar esfuerzo físico alguno, con astenia marcada y luego se agregaron contracciones musculares dolorosas, lo que la motivó asistir a consulta médica. Asociadas a estas manifestaciones se encontraron niveles muy elevados de enzimas musculares. Se comprueba aumento de volumen de la glándula tiroides, así como síntomas y signos sugestivos de hipotiroidismo, el cual se confirma tras dosificaciones de la tirotropina, tiroxina y triyodotironina. Conclusiones: el caso que se presentó es característico del síndrome de Hoffmann, cuya historia clínica detallada y meticulosa evidenció la presentación del hipotiroidismo(AU)
Background: Hoffmann syndrome is defined as the combination of hypothyroidism with myopathy, rigidity, cramps and muscle hypertrophy. This form of thyroid myopathy is rare and usually accompanies patients with severe and long-evolving hypothyroidism.Objective: to describe a case with clinic, hormonal and muscle characteristics of a Hoffmann syndrome, as an exceptional manifestation of hyperthyroidism. Clinical case:16-year-old, female patient begins to feel muscular discomfort due to pain and fatigue, which gradually increased, the myalgia became intense to the point that did not allow any physical effort, with marked asthenia and later contractions were added painful muscles, motivating her attendance to medical consultation. Associated with these manifestations were very high levels of muscle enzymes. Increased thyroid volume and symptoms and signs suggestive of hypothyroidism are confirmed, which is confirmed after dosages of thyrotropin, thyroxine and triiodothyronine. Conclusions: the presented case constitutes a characteristic example of the Hoffmann syndrome, which thanks to a detailed and meticulous clinical history showed the presentation of hypothyroidism(AU)
Asunto(s)
Humanos , Femenino , Adolescente , Hipotiroidismo/clasificación , Hipotiroidismo/diagnóstico , Hipotiroidismo/epidemiología , Hipotiroidismo/terapia , Calambre Muscular/complicaciones , Calambre Muscular/etiología , Distrofias Musculares/complicaciones , Distrofias Musculares/etiología , Enfermedades Musculares/complicacionesRESUMEN
INTRODUCTION: Epidermolysis bullosa (EB) is a congenital disease characterized by fragility of epithelial structures. The skin is the organ primarily affected, resulting in the formation of skin blisters. Some forms of EB may also present mucosal lesions. CASE REPORT: We report the case of a girl with epidermolysis bullosa simplex (EBS) associated with muscular dystrophy secondary to congenital plectin deficiency. She presented severe respiratory tract lesions extending from the oral cavity to the larynx. In particular, we describe our medical and surgical management of the laryngeal lesions, responsible for several episodes of respiratory distress and feeding difficulties. DISCUSSION: Epidermolysis bullosa simplex associated with muscular dystrophy is a rare hereditary form of EB, as fewer than 50 cases have been reported in the literature. This form is characterized by mucosal lesions involving the upper aerodigestive tract, with consequences for feeding, phonation and breathing. Special care must be taken when performing diagnostic and therapeutic procedures to avoid worsening the lesions of this very fragile mucosa. Tracheotomy is a harmful procedure in these patients and should only be considered as a last resort.
Asunto(s)
Epidermólisis Ampollosa Simple/complicaciones , Enfermedades de la Laringe/etiología , Plectina/deficiencia , Consanguinidad , Disnea/etiología , Femenino , Humanos , Lactante , Enfermedades de la Laringe/diagnóstico , Enfermedades de la Laringe/cirugía , Laringoscopía , Distrofias Musculares/etiología , Insuficiencia Respiratoria/etiología , Insuficiencia Respiratoria/cirugíaRESUMEN
OBJECTIVE: To determine the safety and effectiveness of the combined halo gravity traction and dual growing rod technique in achieving and maintaining scoliosis correction while allowing spinal growth. METHODS: From January 2014 to July 2017, 11 patients with dystrophic neurofibromatosis type 1 (NF1)-associated scoliosis, including 7 men and 4 women, underwent combined halo gravity traction and dual growing rod technique procedures. Diagnoses were all dystrophic NF1-associated scoliosis. Patients with a Cobb angle of major curve >60° and flexibility of spine <30% were included in our research. Analysis included age at the time of treatment, levels of instrumentation, number and frequency of lengthening, lengthening distance, and complications. The changes in Cobb angle of scoliosis and T1-S1 length of spine over the treatment period were measured by radiographic evaluation. RESULTS: The average age of treated patients was 7.2 years (range, 5-9 years). Growing rods were lengthened every 6 months through exposure. The mean number of times of lengthening was 3.9 (range, 3-5). The distance of each extension was 1.6 cm (range, 1.0-2.0 cm). The Cobb angle was corrected 41.7% on average after traction, 48.4% after initial surgery, and 53.3% at the last follow-up. T1-S1 length increased 3.4 cm (range, 1.2-5.1 cm) on average over a mean treatment period of 2.2 years, with an average of 1.5 cm/y (range, 0.5-2.3 cm/y). During the treatment period, complication of hook dislodgement occurred in 1 of 11 patients (9.1%). CONCLUSIONS: The combined halo gravity traction and dual growing rod technique can safely and effectively correct NF1-associated scoliosis. This is an ongoing study that requires long-term follow-up.
Asunto(s)
Fijadores Externos , Distrofias Musculares/etiología , Distrofias Musculares/terapia , Neurofibromatosis 1/complicaciones , Escoliosis/etiología , Escoliosis/terapia , Tracción/métodos , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Masculino , Distrofias Musculares/diagnóstico por imagen , Neurofibromatosis 1/diagnóstico por imagen , Aparatos Ortopédicos , Escoliosis/diagnóstico por imagen , Tracción/instrumentación , Resultado del TratamientoRESUMEN
Deficiency of muscle basement membrane (MBM) component laminin-α2 leads to muscular dystrophy congenital type 1A (MDC1A), a currently untreatable myopathy. Laminin--α2 has two main binding partners within the MBM, dystroglycan and integrin. Integrins coordinate both cell adhesion and signalling; however, there is little mechanistic insight into integrin's function at the MBM. In order to study integrin's role in basement membrane development and how this relates to the MBM's capacity to handle force, an itgß1.b-/- zebrafish line was created. Histological examination revealed increased extracellular matrix (ECM) deposition at the MBM in the itgß1.b-/- fish when compared with controls. Surprisingly, both laminin and collagen proteins were found to be increased in expression at the MBM of the itgß1.b-/- larvae when compared with controls. This increase in ECM components resulted in a decrease in myotomal elasticity as determined by novel passive force analyses. To determine if it was possible to control ECM deposition at the MBM by manipulating integrin activity, RGD peptide, a potent inhibitor of integrin-ß1, was injected into a zebrafish model of MDC1A. As postulated an increase in laminin and collagen was observed in the lama2-/- mutant MBM. Importantly, there was also an improvement in fibre stability at the MBM, judged by a reduction in fibre pathology. These results therefore show that blocking ITGß1 signalling increases ECM deposition at the MBM, a process that could be potentially exploited for treatment of MDC1A.
Asunto(s)
Integrina beta1/metabolismo , Laminina/deficiencia , Oligopéptidos/farmacología , Animales , Membrana Basal/metabolismo , Biomarcadores , Colágeno/metabolismo , Modelos Animales de Enfermedad , Susceptibilidad a Enfermedades , Sitios Genéticos , Inmunohistoquímica , Integrina beta1/genética , Ratones Noqueados , Fibras Musculares Esqueléticas/metabolismo , Distrofias Musculares/etiología , Distrofias Musculares/metabolismo , Distrofias Musculares/patología , Fenotipo , Estabilidad Proteica/efectos de los fármacosRESUMEN
Muscle weakness is a nonspecific finding of myopathy of any etiology that include iatrogenic, toxic, endocrinological, infectious, immunologic, and metabolic disorders. Among the metabolic myopathies glutaric aciduria type II (GAII) is an autosomal recessively inherited rare disorder of fatty acid and amino acid metabolisms. The late onset form is heterogeneous in terms of symptomatology and severity and for the cases that chronic manifestations of lipid storage myopathy are the only clues for the disease, differential diagnosis can be challenging. Here we report two cases of GAII: the first one was 18-year old boy who presented with proximal muscle weakness and in another center, he was diagnosed as polymyositis and treated with immunosuppressive therapies. He admitted to our clinic with ongoing muscle weakness and symptoms that were related to the side effects of immunosuppressive therapies. The second case was also presented with muscle weakness. For both cases, muscle biopsies and urinary organic acid analyses were consistent with the diagnosis of GAII. To differentiate inflammatory myositis from non-inflammatory myopathies; rheumatic symptoms, accompanying complaints of the patient and autoantibody positivity can be helpful. To our knowledge this is the first report to underline the differential diagnosis of inflammatory myopathies from metabolic myopathies.
Asunto(s)
Acil-CoA Deshidrogenasa/deficiencia , Enfermedades de Inicio Tardío , Errores Innatos del Metabolismo Lipídico , Deficiencia Múltiple de Acil Coenzima A Deshidrogenasa , Músculo Esquelético/patología , Distrofias Musculares , Miositis/diagnóstico , Adolescente , Biopsia/métodos , Carnitina/administración & dosificación , Diagnóstico Diferencial , Femenino , Humanos , Enfermedades de Inicio Tardío/diagnóstico , Enfermedades de Inicio Tardío/fisiopatología , Errores Innatos del Metabolismo Lipídico/diagnóstico , Errores Innatos del Metabolismo Lipídico/etiología , Errores Innatos del Metabolismo Lipídico/fisiopatología , Masculino , Micronutrientes/administración & dosificación , Deficiencia Múltiple de Acil Coenzima A Deshidrogenasa/diagnóstico , Deficiencia Múltiple de Acil Coenzima A Deshidrogenasa/metabolismo , Deficiencia Múltiple de Acil Coenzima A Deshidrogenasa/fisiopatología , Debilidad Muscular/diagnóstico , Debilidad Muscular/etiología , Distrofias Musculares/diagnóstico , Distrofias Musculares/etiología , Distrofias Musculares/fisiopatología , Riboflavina/administración & dosificación , Índice de Severidad de la Enfermedad , Urinálisis/métodos , Adulto JovenRESUMEN
PURPOSE OF REVIEW: Muscle and bone are intrinsically linked, and therefore, it is not surprising that many muscular dystrophies are associated with impaired bone health and increased risk of osteoporosis. Osteoporotic fracture is an important and preventable cause of morbidity and mortality. This article will firstly review the general causes of impaired bone health in muscular dystrophies and then focus on the evidence available for the diagnosis and treatment of osteoporosis in specific conditions. RECENT FINDINGS: With the exception of DMD, there is a paucity of data regarding bone health in muscular dystrophies. However, it appears that in common with all types of muscular dystrophies that cause a significant level of muscle weakness and disability there is an increased risk of falls, fractures and decreased vitamin D levels. A better understanding of the extent of the impaired bone health and underlying causes could help to identify potential new therapeutic agents and aid clinical care. SUMMARY: It would be prudent for clinicians to assess fracture risk in their muscular dystrophy patients and if appropriate, arrange surveillance and recommend vitamin D supplementation. Additionally, fracture should be considered in any patient presenting with new-onset bone pain.
Asunto(s)
Enfermedades Óseas/etiología , Huesos/patología , Distrofias Musculares/complicaciones , Distrofias Musculares/patología , Enfermedades Óseas/terapia , Humanos , Distrofias Musculares/etiología , Distrofias Musculares/terapia , Fracturas Osteoporóticas/epidemiología , Fracturas Osteoporóticas/etiología , Medición de RiesgoRESUMEN
This case report presents investigations of muscle problems in three male water buffaloes (1-2 years) kept extensively (loose housing, pasture). The bulls were presented because of listlessness and increased lying periods. They displayed difficulties to stand up, a stilted gait, and tremor in the legs. The determination of the selenium concentration by the measurement of glutathione peroxidase activity in whole blood samples (EDTA) demonstrated selenium deficiency in all three buffaloes. This confirmed the tentative diagnosis of nutritive myodystrophy due to selenium deficiency. Following a single injection of 1500 mg all-rac-alpha-tocopherol acetate and 11 mg sodium selenite, the bulls recovered clinically. The whole blood samples taken subsequently from seven adult water buffaloes on the farm showed selenium deficiency in all animals. Consequently, slow-release multi-trace element boluses were administered once orally - as far as possible - to all adult animals of the herd. After 1 year, a good to very good selenium supply was observed in all these buffaloes, except for one cow, in which bolus application had failed.
Asunto(s)
Búfalos , Enfermedades Carenciales/veterinaria , Agricultura Orgánica , Selenio/deficiencia , Crianza de Animales Domésticos/métodos , Animales , Enfermedades Carenciales/complicaciones , Enfermedades Carenciales/tratamiento farmacológico , Granjas , Masculino , Distrofias Musculares/etiología , Selenito de Sodio/administración & dosificación , alfa-Tocoferol/administración & dosificaciónRESUMEN
BACKGROUND: Our previous study demonstrated that ventilators increase diaphragmatic lipid accumulation in rabbits, but their cellular mechanism is poorly understood. Mammalian target of rapamycin (mTOR) plays an important role in atherosclerosis in rat vascular smooth muscle cells. The present study investigated the role of mTOR pathway activation in the diaphragmatic muscle of ventilated rats and hypoxia-induced C2C12 cells. MATERIALS AND METHODS: Male Sprague-Dawly rats were randomized into a control group (n = 8), controlled mechanical ventilation (CMV) group (n = 8), and CMV + Rapa group (n = 8). We evaluated the diaphragmatic contractility, lipid accumulation, and protein expression of the mTOR pathways. To explore the mechanism underlying ventilator-induced lipid accumulation, we observed protein expression of the mTOR and low-density lipoprotein receptor (LDLr) pathways in C2C12 cells under hypoxic and mTOR pathway inhibitor treatments. RESULTS: Compared with the control group, there was a significant decrease in the peak twitch and peak tetanic forces in the CMV group (384.24 ± 70.39 versus 496.33 ± 78.64 g/cm2, P < 0.05, and 869.24 ± 76.67 versus 1090.72 ± 118.91 g/cm2, P < 0.05, respectively). There was a significant increase in peak twitch and peak tetanic forces in the CMV + Rapa group compared with that in the CMV group (501.81 ± 23.15 versus 384.24 ± 70.39 g/cm2, P < 0.05, and 992.91 ± 88.99 versus 869.24 ± 76.67 g/cm2, P < 0.05, respectively). In the CMV group, there were significant increases in lipid accumulation (0.086 ± 0.009 versus 0.005 ± 0.002, P < 0.05) and expression of mTOR in diaphragmatic fibers compared with those in the control group (P < 0.05). Rapamycin prevented lipid accumulation in rats of the CMV + Rapa group compared with that in the CMV group rats (0.024 ± 0.004 versus 0.086 ± 0.009, P < 0.05). Compared with the CMV group, there was a significant decrease in the phosphorylated protein expression levels of mTOR in rats of the CMV + Rapa group (P < 0.05). Hypoxic conditions activated the mTOR and LDLr pathways in C2C12 cells, which were correlated with an increase in expression of the mTOR and LDLr pathways compared with the control group (P < 0.05). In C2C12 cells treated with hypoxia + rapamycin, activation of the mTOR and LDLr pathways was blocked compared with C2C12 cells treated with hypoxia (P < 0.05). CONCLUSIONS: These data suggest that CMV and hypoxia-induced activation of the mTOR pathway, resulting in lipid accumulation, and impaired the diaphragmatic contractile function. Therefore, pharmacologic agents that inhibit the mTOR pathway could potentially be useful for mitigating the diaphragmatic contractile dysfunction induced by mechanical ventilation.
Asunto(s)
Diafragma/efectos de los fármacos , Metabolismo de los Lípidos/efectos de los fármacos , Distrofias Musculares/prevención & control , Respiración Artificial/efectos adversos , Sirolimus/farmacología , Serina-Treonina Quinasas TOR/metabolismo , Animales , Hipoxia de la Célula/fisiología , Diafragma/metabolismo , Diafragma/fisiopatología , Modelos Animales de Enfermedad , Electromiografía , Humanos , Masculino , Ratones , Contracción Muscular/efectos de los fármacos , Contracción Muscular/fisiología , Distrofias Musculares/diagnóstico , Distrofias Musculares/etiología , Distrofias Musculares/fisiopatología , Fosforilación/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Receptores de LDL/metabolismo , Transducción de Señal/efectos de los fármacos , Sirolimus/uso terapéutico , Serina-Treonina Quinasas TOR/antagonistas & inhibidores , Resultado del TratamientoRESUMEN
Skeletal muscle stem cells, originally termed satellite cells for their position adjacent to differentiated muscle fibers, are absolutely required for the process of skeletal muscle repair and regeneration. In the last decade, satellite cells have become one of the most studied adult stem cell systems and have emerged as a standard model not only in the field of stem cell-driven tissue regeneration but also in stem cell dysfunction and aging. Here, we provide background in the field and discuss recent advances in our understanding of muscle stem cell function and dysfunction, particularly in the case of aging, and the potential involvement of muscle stem cells in genetic diseases such as the muscular dystrophies.